• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

感染、抗治疗与结直肠癌和腺瘤风险:一项观察性研究及荟萃分析

infection, anti- treatment and risk of colorectal cancer and adenoma: an observational study and a meta-analysis.

作者信息

Li Xue, Tao Huan-Qing, Zhao Ji-Er, Zhu Juan, Du Ling-Bin, Gerhard Markus, Li Wen-Qing

机构信息

Department of Cancer Prevention, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, Zhejiang, China.

Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, 211166, Jiangsu, China.

出版信息

EClinicalMedicine. 2025 Jun 9;84:103299. doi: 10.1016/j.eclinm.2025.103299. eCollection 2025 Jun.

DOI:10.1016/j.eclinm.2025.103299
PMID:40547441
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12179743/
Abstract

BACKGROUND

Recent studies suggest a possible link between infection and risk of colorectal cancer. We examined the association between infection, anti- treatment, and colorectal cancer and its precursor, adenoma, based on an observational study and a meta-analysis.

METHODS

The observational study part included 3475 participants undergoing colonoscopy and testing within the framework of a screening program in Zhejiang Province, China between March 8 and December 29, 2023. Logistic regression models were used to analyze the associations between infection and the risk of colorectal cancer and adenoma. Additionally, a meta-analysis was conducted on the associations of infection, anti- treatment and risk of colorectal cancer and adenoma. Three databases (PubMed, Embase, and Cochrane Library) were searched for relevant studies from inception up to April 9, 2025. Two reviewers independently screened records for eligibility, extracted summary-level data and assessed study quality. Random-effects models were used to calculate the pooled odds ratios (ORs) and 95% confidence intervals (CIs). Study quality was evaluated using the Newcastle-Ottawa Scale for case-control and cohort studies, and adhering to the Agency for Healthcare Research and Quality's recommendations for cross-sectional studies. Heterogeneity was quantified using statistics and subgroup analyses were conducted to identify potential sources. We used funnel plots to assess publication bias, and Duval and Tweedie's "trim-and-fill" analysis to correct potential bias. Certainty of evidence was assessed using the Grading of Recommendations, Assessment, Development, and Evaluation system. The protocol for meta-analysis was registered in PROSPERO (CRD42024566640).

FINDINGS

The observational study found a statistically significant association between infection and the odds of colorectal cancer (n = 31, OR = 2.57, 95% CI: 1.26-5.39) and adenoma (n = 1245, OR = 1.37, 95% CI: 1.19-1.59), especially for advanced adenoma (n = 486, OR = 1.94, 95% CI: 1.59-2.38), compared with normal or non-adenomatous lesions (n = 2199). Meta-analysis of this and 54 other studies, with a total of 48,945,236 participants, found that infection was positively associated with colorectal cancer (OR = 1.59, 95% CI: 1.39-1.82, = 89%) and adenoma (OR = 1.47, 95% CI: 1.36-1.59, = 88%), especially with advanced adenoma (OR = 1.77, 95% CI: 1.56-2.00, = 65%). The OR of overall colorectal neoplasia (colorectal cancer or adenoma) was 1.49 (95% CI: 1.39-1.60, = 91%). Based on meta-analysis of 3 retrospective studies, anti- treatment was associated with a reduced overall risk of colorectal neoplasia (OR = 0.44, 95% CI: 0.20-0.97, = 93%).

INTERPRETATION

infection may represent a significant risk factor for the development of colorectal cancer. The effect of anti- treatment on colorectal cancer incidence and mortality necessitates further investigation through large-scale, randomized controlled trials with prolonged follow-up durations.

FUNDING

This work was supported by National Natural Science Foundation of China (No. 82404341, No. 82273704), Noncommunicable Chronic Diseases-National Science and Technology Major Project (No. 2023ZD0501400-2023ZD0501402), Beijing Hospitals Authority's Ascent Plan (DFL20241102), Peking University Medicine Fund for World's Leading Discipline or Discipline Cluster Development (No. BMU2022XKQ004), Science Foundation of Peking University Cancer Hospital (No. BJCH2024BJ02), Healthy Zhejiang One Million People Cohort (K-20230085), German Research Foundation (DFG, GE 2042/24-1).

摘要

背景

近期研究表明感染与结直肠癌风险之间可能存在联系。我们基于一项观察性研究和一项荟萃分析,研究了感染、抗治疗与结直肠癌及其癌前病变腺瘤之间的关联。

方法

观察性研究部分纳入了2023年3月8日至12月29日在中国浙江省一项筛查项目框架内接受结肠镜检查和检测的3475名参与者。采用逻辑回归模型分析感染与结直肠癌及腺瘤风险之间的关联。此外,对感染、抗治疗与结直肠癌及腺瘤风险的关联进行了荟萃分析。检索了三个数据库(PubMed、Embase和Cochrane图书馆),以查找从起始到2025年4月9日的相关研究。两名评审员独立筛选记录以确定其是否符合条件,提取汇总水平的数据并评估研究质量。采用随机效应模型计算合并比值比(OR)和95%置信区间(CI)。使用纽卡斯尔-渥太华量表对病例对照研究和队列研究的质量进行评估,并遵循医疗保健研究与质量机构对横断面研究的建议。使用I²统计量对异质性进行量化,并进行亚组分析以确定潜在来源。我们使用漏斗图评估发表偏倚,并使用杜瓦尔和特威迪的“修剪和填充”分析来纠正潜在偏倚。使用推荐分级、评估、制定和评价系统评估证据的确定性。荟萃分析方案已在PROSPERO(CRD42024566640)中注册。

结果

观察性研究发现,与正常或非腺瘤性病变(n = 2199)相比,感染与结直肠癌(n = 31,OR = 2.57,95% CI:1.26 -

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e51/12179743/27d001a68d0f/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e51/12179743/9b5642b9fa38/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e51/12179743/e2175cecb76a/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e51/12179743/6fb066d43adb/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e51/12179743/de4239df60cb/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e51/12179743/af4acec9fc4f/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e51/12179743/27d001a68d0f/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e51/12179743/9b5642b9fa38/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e51/12179743/e2175cecb76a/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e51/12179743/6fb066d43adb/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e51/12179743/de4239df60cb/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e51/12179743/af4acec9fc4f/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e51/12179743/27d001a68d0f/gr6.jpg

相似文献

1
infection, anti- treatment and risk of colorectal cancer and adenoma: an observational study and a meta-analysis.感染、抗治疗与结直肠癌和腺瘤风险:一项观察性研究及荟萃分析
EClinicalMedicine. 2025 Jun 9;84:103299. doi: 10.1016/j.eclinm.2025.103299. eCollection 2025 Jun.
2
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.成人全身麻醉后预防术后恶心呕吐的药物:网状Meta分析
Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2.
3
Non-invasive diagnostic tests for Helicobacter pylori infection.幽门螺杆菌感染的非侵入性诊断测试。
Cochrane Database Syst Rev. 2018 Mar 15;3(3):CD012080. doi: 10.1002/14651858.CD012080.pub2.
4
Intracavity lavage and wound irrigation for prevention of surgical site infection.腔内灌洗和伤口冲洗预防手术部位感染
Cochrane Database Syst Rev. 2017 Oct 30;10(10):CD012234. doi: 10.1002/14651858.CD012234.pub2.
5
Non-pharmacological interventions for preventing delirium in hospitalised non-ICU patients.非 ICU 住院患者预防谵妄的非药物干预措施。
Cochrane Database Syst Rev. 2021 Jul 19;7(7):CD013307. doi: 10.1002/14651858.CD013307.pub2.
6
Non-pharmacological interventions for preventing delirium in hospitalised non-ICU patients.非 ICU 住院患者预防谵妄的非药物干预措施。
Cochrane Database Syst Rev. 2021 Nov 26;11(11):CD013307. doi: 10.1002/14651858.CD013307.pub3.
7
Dietary fibre for the prevention of recurrent colorectal adenomas and carcinomas.膳食纤维用于预防复发性结直肠腺瘤和癌。
Cochrane Database Syst Rev. 2017 Jan 8;1(1):CD003430. doi: 10.1002/14651858.CD003430.pub2.
8
Selenium for preventing cancer.硒预防癌症。
Cochrane Database Syst Rev. 2018 Jan 29;1(1):CD005195. doi: 10.1002/14651858.CD005195.pub4.
9
Electronic cigarettes for smoking cessation.电子烟戒烟。
Cochrane Database Syst Rev. 2024 Jan 8;1(1):CD010216. doi: 10.1002/14651858.CD010216.pub8.
10
Electronic cigarettes for smoking cessation.用于戒烟的电子烟。
Cochrane Database Syst Rev. 2025 Jan 29;1(1):CD010216. doi: 10.1002/14651858.CD010216.pub9.

本文引用的文献

1
Risk of Gastric Adenocarcinoma After Eradication of Helicobacter pylori.幽门螺杆菌根除后胃腺癌的风险
Gastroenterology. 2025 Feb 7. doi: 10.1053/j.gastro.2025.01.239.
2
Eradication Therapy to Prevent Gastric Cancer in Helicobacterpylori-Positive Individuals: Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Studies.根除治疗预防幽门螺杆菌阳性个体患胃癌:随机对照试验和观察性研究的系统评价与荟萃分析
Gastroenterology. 2025 Jan 15. doi: 10.1053/j.gastro.2024.12.033.
3
Helicobacter pylori Eradication Therapy and the Risk of Colorectal Cancer: A Population-Based Nationwide Cohort Study in Sweden.
幽门螺杆菌根除治疗与结直肠癌风险:瑞典基于人群的全国队列研究。
Helicobacter. 2024 Nov-Dec;29(6):e70001. doi: 10.1111/hel.70001.
4
Impacts of Helicobacter pylori infection and eradication on gastrointestinal microbiota: An up-to-date critical review and future perspectives.幽门螺杆菌感染与根除对胃肠道微生物群的影响:最新批判性综述与未来展望
Chin Med J (Engl). 2024 Dec 5;137(23):2833-2842. doi: 10.1097/CM9.0000000000003348. Epub 2024 Nov 6.
5
Effects and mechanisms of infection on the occurrence of extra-gastric tumors.感染对胃外肿瘤发生的影响及其机制。
World J Gastroenterol. 2024 Oct 7;30(37):4090-4103. doi: 10.3748/wjg.v30.i37.4090.
6
Association of Antibody Responses to Proteins with Colorectal Adenoma and Colorectal Cancer.针对蛋白质的抗体反应与结肠直肠腺瘤和结肠直肠癌的关联。
Pathogens. 2024 Oct 14;13(10):897. doi: 10.3390/pathogens13100897.
7
Gastric cancer prevention by community eradication of Helicobacter pylori: a cluster-randomized controlled trial.社区消除幽门螺杆菌预防胃癌:一项整群随机对照试验。
Nat Med. 2024 Nov;30(11):3250-3260. doi: 10.1038/s41591-024-03153-w. Epub 2024 Jul 30.
8
Association of Helicobacter pylori infection with colorectal polyps/adenomas: A single-center cross-sectional study.幽门螺杆菌感染与结直肠息肉/腺瘤的关系:一项单中心横断面研究。
Cancer Epidemiol. 2024 Oct;92:102626. doi: 10.1016/j.canep.2024.102626. Epub 2024 Jul 29.
9
Cancer incidence and mortality in China, 2022.2022年中国癌症发病率与死亡率
J Natl Cancer Cent. 2024 Feb 2;4(1):47-53. doi: 10.1016/j.jncc.2024.01.006. eCollection 2024 Mar.
10
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.2022 年全球癌症统计数据:全球 185 个国家和地区 36 种癌症的发病率和死亡率全球估计数。
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.